Study of adenylyl cyclase-GαS interactions and identification of novel AC ligands
- 218 Downloads
Adenylyl cyclases (ACs) are membrane bound enzymes that catalyze the production of cAMP from ATP in response to the activation by G-protein Gαs. Different isoforms of ACs are ubiquitously expressed in different tissues involved in regulatory mechanisms in response to specific stimulants. There are 9 AC isoforms present in humans, with AC5 and AC6 proposed to play a vital role in cardiac functions. The activity of AC6 is sensitive to nitric oxide, such that nitrosylation of the protein might regulate its function. However, the information on structural determinants of nitrosylation in ACs and how they interact with Gαs is limited. Here we used homology modeling to build a molecular model of human AC6 bound to Gαs. Based on this 3D model, we predict the nitrosylation amenable cysteines, and identify potential novel ligands of AC6 using virtual ligand screening. Our model suggests Cys1004 in AC6 (subunit C2) and Cys174 in Gαs present at the AC-Gαs interface as the possible residues that might undergo reversible nitrosylation. Docking analysis predicted novel ligands of AC6 that include forskolin-based compounds and its derivatives. Further work involving site-directed mutagenesis of the predicted residues will allow manipulation of AC activity using novel ligands, and crucial insights on the role of nitrosylation of these proteins in pathophysiological conditions.
KeywordsAdenylyl cyclase (AC) Cyclic adenosine monophosphate (cAMP) Protein modeling Ligand screening Nitric oxide (NO) Forskolin
The work was supported by operating grants from Natural Sciences and Engineering Research Council (NSERC) to PC, Research Manitoba (RM) and Manitoba Chemosensory Biology (MCSB) catalyst grant to SD and University of Manitoba (Faculty of Science Interdisciplinary Grant) to JLS.
Compliance with ethical standards
Conflict of interest
All the authors have approved the final manuscript and declared that they have no conflict of interest.
All methods performed in this study were in accordance with the ethical standards of the institution.
- 1.Smit MJ, Iyengar R (1998) Mammalian adenylyl cyclases. Adv Second Messenger Phosphoprot Res 32:1–21Google Scholar
- 3.Santhosh KT, Elkhateeb O, Nolette N, Outbih O, Halayko AJ, Dakshinamurti S (2011) Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes. Br J Pharmacol 163(6):1223–1236. https://doi.org/10.1111/j.1476-5381.2011.01306.xCrossRefPubMedPubMedCentralGoogle Scholar
- 6.Mou TC, Gille A, Suryanarayana S, Richter M, Seifert R, Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 2′,3′-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70(3):878–886. https://doi.org/10.1124/mol.106.026427CrossRefPubMedGoogle Scholar
- 8.Nelson CP, Rainbow RD, Brignell JL, Perry MD, Willets JM, Davies NW, Standen NB, Challiss RA (2011) Principal role of adenylyl cyclase 6 in K(+) channel regulation and vasodilator signalling in vascular smooth muscle cells. Cardiovasc Res 91(4):694–702. https://doi.org/10.1093/cvr/cvr137CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Ishikawa Y, Sorota S, Kiuchi K, Shannon RP, Komamura K, Katsushika S, Vatner DE, Vatner SF, Homcy CJ (1994) Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest 93(5):2224–2229. https://doi.org/10.1172/JCI117219CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, Liu J, Vatner DE, Sadoshima J, Vatner SF, Ishikawa Y (2003) Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100(17):9986–9990. https://doi.org/10.1073/pnas.1733772100CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Gao MH, Lai NC, Giamouridis D, Kim YC, Tan Z, Guo T, Dillmann WH, Suarez J, Hammond HK (2016) Cardiac-directed expression of adenylyl cyclase catalytic domain reverses cardiac dysfunction caused by sustained beta-adrenergic receptor stimulation. JACC 1(7):617–629. https://doi.org/10.1016/j.jacbts.2016.08.004PubMedPubMedCentralGoogle Scholar
- 13.Liu X, Thangavel M, Sun SQ, Kaminsky J, Mahautmr P, Stitham J, Hwa J, Ostrom RS (2008) Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts. Naunyn Schmiedebergs Arch Pharmacol 377(4–6):359–369. https://doi.org/10.1007/s00210-007-0196-0CrossRefPubMedGoogle Scholar
- 17.Qin Y, Dey A, Daaka Y (2013) Protein s-nitrosylation measurement. Methods Enzymol 522:409–425. https://doi.org/10.1016/B978-0-12-407865-9.00019-4CrossRefPubMedGoogle Scholar
- 20.Jeffrey Man HS, Tsui AK, Marsden PA (2014) Nitric oxide and hypoxia signaling. Vitam Horm 96:161–192. https://doi.org/10.1016/B978-0-12-800254-4.00007-6CrossRefPubMedGoogle Scholar
- 34.Tatee T, Narita A, Narita K, Izumi G, Takahira T, Sakurai M, Fujita A, Hosono M, Yamashita K, Enomoto K, Shiozawa A (1996) Forskolin derivatives. I. Synthesis, and cardiovascular and adenylate cyclase-stimulating activities of water-soluble forskolins. Chem Pharm Bull (Tokyo) 44(12):2274–2279CrossRefGoogle Scholar